Tph

Monument Reports Second Quarter Fiscal 2024 (“Q2 FY2024”) Results

Retrieved on: 
星期五, 三月 1, 2024
Odyssey, Acquisition, Monument, DMT, Total, Gabanintha, Western Australia, Tph, YTD, Mining, Retirement, Sale, Gold, London Bullion Market Association, TSF, Public expenditure, Atlas, Economics, Atlas Copco, Depreciation, Cryptocurrency

The mill processed 192,217 tonnes of sulphide ore, achieving a head grade of 1.55g/t and a recovery rate of 71.10%.

Key Points: 
  • The mill processed 192,217 tonnes of sulphide ore, achieving a head grade of 1.55g/t and a recovery rate of 71.10%.
  • Availability of the flotation plant also improved at 90% during Q2 2024 as a result of ongoing optimization.
  • Accommodation and catering facilities were fully operational during the quarter and equipped to support administrative, exploration, and mining activities.
  • Both Monument and Odyssey agreed to defer the payment by six months after the date of satisfaction of the milestone, specifically by February 2, 2024.

TRI Pointe Group, Inc. Announces Third Quarter 2020 Earnings Release and Conference Call Date

Retrieved on: 
星期二, 九月 29, 2020
TRI Pointe Group, New York Stock Exchange, Tph, New York City, Industries

TRI Pointe Group, Inc. (NYSE: TPH) announced today that it will release its financial results for the third quarter of 2020 before the market opens on Thursday, October 22, 2020.

Key Points: 
  • TRI Pointe Group, Inc. (NYSE: TPH) announced today that it will release its financial results for the third quarter of 2020 before the market opens on Thursday, October 22, 2020.
  • The Company will host a conference call on the same day to discuss the results at 7:00 AM Pacific (10:00 AM Eastern).
  • The call will be hosted by Doug Bauer, Chief Executive Officer, Tom Mitchell, Chief Operating Officer and Glenn Keeler, Chief Financial Officer.
  • Headquartered in Irvine, California, TRI Pointe Group, Inc. (NYSE: TPH) is a family of premium, regional homebuilders that designs, builds, and sells homes in major U.S. markets.

Byron Pope named Vice President of ESG & Investor Relations for ChampionX

Retrieved on: 
星期一, 八月 24, 2020
Ethical investment, ESG, Tph, Ethical banking, Environmentalism, Governance, Articles

THE WOODLANDS, Texas, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ChampionX Corporation (ChampionX) (NYSE: CHX) announced today that Byron Pope has been appointed to the newly created role of Vice President ESG & Investor Relations, effective immediately.

Key Points: 
  • THE WOODLANDS, Texas, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ChampionX Corporation (ChampionX) (NYSE: CHX) announced today that Byron Pope has been appointed to the newly created role of Vice President ESG & Investor Relations, effective immediately.
  • In this new role, Byron will lead company-wide ESG (Environmental, Social, Governance) efforts for ChampionX and be the principal contact for ChampionX investors.
  • Byron joins ChampionX from Tudor, Pickering, Holt & Co. (TPH) and has 26 years of experience covering the energy sector.
  • In addition to his ESG role, Byron will be taking over investor relations responsibilities from David Skipper.

Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019

Retrieved on: 
星期二, 九月 24, 2019
Amino acids, Hydroxyarenes, Dietary Supplements, Tryptophan hydroxylase, Serotonin, Phenylalanine hydroxylase, Tryptophan, Tph

The poster will be presented on Tuesday, October 1 at 12:50 CEST and will be available on the Publications page of the Altavant website following its presentation at the congress.

Key Points: 
  • The poster will be presented on Tuesday, October 1 at 12:50 CEST and will be available on the Publications page of the Altavant website following its presentation at the congress.
  • Rodatristat is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin.
  • Altavant is currently evaluating rodatristat ethyl in the ELEVATE1 proof-of-concept Phase 2a study in patients with PAH.
  • Rodatristat ethyl is currently being evaluated in the ELEVATE1 Phase 2 Study for patients with PAH.